Starodubtseva Natalia, Tokareva Alisa, Kononikhin Alexey, Brzhozovskiy Alexander, Bugrova Anna, Kukaev Evgenii, Poluektova Alina, Frankevich Vladimir, Nikolaev Evgeny, Sukhikh Gennady
V.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, 117997 Moscow, Russia.
Project Center of Omics Technologies and Advanced Mass Spectrometry, 121205 Moscow, Russia.
Int J Mol Sci. 2025 Aug 18;26(16):7970. doi: 10.3390/ijms26167970.
The maternal circulating proteome reflects critical physiological adaptations during pregnancy, yet standardized reference profiles for early gestation are lacking. In this prospective study, we employed targeted liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) with stable isotope-labeled (SIS) standards to characterize the serum proteome of 83 women with uncomplicated singleton pregnancies between 11 and 13 weeks' gestation. Robust analysis quantified 115 proteins (83% of targets), with 101 meeting ICH M10 standards. These included 38 FDA-approved, 19 CVD-related, and 25 CLIA-approved biomarkers. We identified 43 proteins significantly associated ( < 0.05) with gestational age, maternal factors (BMI, age, parity, and myomas), and fetal sex. Key findings included identification of 12 proteins significantly associated with trisomy risk (|R| = 0.21-0.45, < 0.05) and extreme physiological variability in pregnancy zone protein (PZP, 123.9-fold), followed by apolipoprotein (a) (LPA; 9.9-fold) and pregnancy-associated plasma protein A (PAPP-A, 9.3-fold). In contrast, hemopexin (HPX) demonstrated remarkable stability (CV = 8.5%), suggesting its utility as a reference marker. The study successfully implemented multiples of the median (MoM) transformation for clinical standardization of protein profiles, with RobNorm proving particularly effective for batch-effect correction in our dataset. These methodological advances, combined with the establishment of comprehensive pregnancy-specific reference ranges, provide a valuable foundation for future research. The optimized analytical framework and protein signatures identified in this work not only enable the development of next-generation screening approaches but also offer new insights into the molecular adaptations occurring during early pregnancy.
母体循环蛋白质组反映了孕期关键的生理适应性变化,但目前仍缺乏孕早期的标准化参考图谱。在这项前瞻性研究中,我们采用靶向液相色谱 - 多反应监测 - 质谱联用技术(LC - MRM - MS),结合稳定同位素标记(SIS)标准品,对83例孕11至13周单胎妊娠且无并发症的孕妇血清蛋白质组进行了表征。稳健分析定量了115种蛋白质(占目标蛋白的83%),其中101种符合国际人用药品注册技术协调会(ICH)M10标准。这些蛋白质包括38种经美国食品药品监督管理局(FDA)批准的、19种与心血管疾病(CVD)相关的以及25种经临床实验室改进修正案(CLIA)批准的生物标志物。我们鉴定出43种蛋白质与孕周、母体因素(体重指数、年龄、产次和肌瘤)以及胎儿性别显著相关(P < 0.05)。主要发现包括鉴定出12种与三体风险显著相关的蛋白质(|R| = 0.21 - 0.45,P < 0.05),以及妊娠区蛋白(PZP)存在极大的生理变异性(123.9倍),其次是载脂蛋白(a)(LPA;9.9倍)和妊娠相关血浆蛋白A(PAPP - A,9.3倍)。相比之下,血红素结合蛋白(HPX)表现出显著的稳定性(变异系数CV = 8.5%),表明其作为参考标志物的实用性。该研究成功实施了蛋白质谱临床标准化的中位数倍数(MoM)转换,结果表明RobNorm在我们的数据集中对批次效应校正特别有效。这些方法学进展,结合建立的全面的孕期特异性参考范围,为未来研究提供了有价值的基础。本研究中优化的分析框架和鉴定出的蛋白质特征不仅有助于开发下一代筛查方法,还为孕早期发生的分子适应性变化提供了新的见解。